Novartis: Alcon withdraws micro-stents for cataract surgery
(CercleFinance.com) - Novartis' Alcon removed its micro-stents for surgical glaucoma from the market on Wednesday after a study revealed a statistically significant endothelial cell loss in patients who have received the product.
Novartis' eye care unit announced an immediate, voluntary market withdrawal of its CyPass Micro-Stent, advising surgeons to immediately cease further implantation and to return any unused devices.
The decision was based on five-year data from a long-term safety study showing patients experienced statistically significant endothelial cell loss compared to the group that underwent cataract surgery alone, Alcon said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Novartis' eye care unit announced an immediate, voluntary market withdrawal of its CyPass Micro-Stent, advising surgeons to immediately cease further implantation and to return any unused devices.
The decision was based on five-year data from a long-term safety study showing patients experienced statistically significant endothelial cell loss compared to the group that underwent cataract surgery alone, Alcon said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.